Kornimate/medical-research-clean huggingface dataset:
capillary refill time calculated with a video-assisted method has a better reproducibility than visual method in critically ill patients

Conditions: Intensive Care Unit; Mortality; Reliability

Summary: capillary refill time is the time it takes for the skin to regain its initial colour after moderate pressure. it is usually performed on the patient index finger, middle finger or ring finger with the examiner's thumb and index finger for five seconds, three measurements having to be averaged. capillary refill time has a dependent operator character, but it has been shown to be accurately correlated with 14-day mortality in septic shock, hospitalisation need in pediatric population. the purpose of this project is to show that capillary refill time obtained by a video-assisted method has a better inter- and intra-observer reproducibility than capillary refill time obtained by a visual method.


Eligibility criteria:
inclusion criteria: * age \> 18 years * hospitalized in icu * patient or family /relative with inclusion authorization exclusion criteria: * pregnant or lactating women * under protection (guardianship, curators, reinforced curators)

Keywords: capillary refill time intensive care unit mortality reliability
enhancing recovery in early schizophrenia

Conditions: Schizophrenia

Summary: current antipsychotic treatments of schizophrenia are only partially effective, and their use is often associated with serious side effects. cannabidiol is a natural counterpart of the psychoactive component of marijuana, delta-9- tetrahydrocannabinol and has no psychotomimetic or addictive properties. in a controlled clinical trial of cannabidiol versus amisulpride in acute paranoid schizophrenia we showed a statistically significant clinical improvement in all symptoms clusters of schizophrenia compared to baseline with either treatment. cannabidiol displayed a significantly superior side-effect profile in particular regarding prolactin elevation, extrapyramidal symptoms and weight gain. the favorable side-effect profile and potentially novel mechanism of action identify this molecule as a potential antipsychotic. however, long-term safety and efficacy data is still lacking. this study is to evaluate the efficacy and safety of the novel compound cannabidiol in the maintenance treatment of schizophrenia in comparison to placebo as an add-on to an established treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone, in a 12-months, double-blind, parallel-group, randomized, placebo-controlled clinical trial. thereby, relevant data on cannabidiol's antipsychotic potential will be gained.


Eligibility criteria:
inclusion criteria: * informed consent given by the subject * dsm-iv-tr diagnosis of schizophrenic psychosis (295.10-30, 295.90) * first documented diagnosis of schizophrenia must not be no older than seven years. * patients must receive a stable dose of amisulpride, aripiprazole, olanzapine, quetiapine or risperidone (tau: treatment as usual) at least 4 weeks prior to inclusion in the study to ensure that the maximal effect of the previous medication has been received. * initial panss total score of ≤ 75 at baseline. * proper contraception in female patients of childbearing potential * body mass index between 18 and 40. exclusion criteria: * lack of accountability * positive urine drug-screening for illicit drugs at screening (except cannabinoids and benzodiazepines) * serious suicidal risk at screening visit * other relevant interferences of axis 1 according to diagnostic evaluation (mini) including residual forms of schizophrenia. * other relevant neurological or other medical disorders * pregnancy or lactation.
a non-interventional study evaluating rheumatoid arthritis participants treated with tocilizumab (roactemra/actemra)

Conditions: Rheumatoid Arthritis

Summary: this non-interventional study evaluated the use and efficacy of tocilizumab (roactemra/actemra) in participants with moderate to severe rheumatoid arthritis. eligible participants initiated on tocilizumab treatment according to the approved label were followed for 6 months.


Eligibility criteria:
inclusion criteria: * adult participants, \>/= 18 years of age * moderate to severe rheumatoid arthritis according to the revised (1987) american college of rheumatology (acr) criteria * participants in whom the treating physician made the decision to commence tocilizumab treatment (in accordance with the local label); this could include participants who had received tocilizumab treatment within 8 weeks prior to the enrollment visit exclusion criteria: * participants who had received tocilizumab more than 8 weeks prior to the enrollment visit * participants who had previously received tocilizumab in a clinical trial or for compassionate use * treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever was longer) before starting treatment with tocilizumab * history of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis
artemis: ravulizumab to protect patients with ckd from csa-aki and make

Conditions: Chronic Kidney Disease; CKD; Cardiac Disease; Cardiopulmonary Bypass

Summary: the primary objective of this study is to assess the efficacy of a single dose of ravulizumab iv compared with placebo in reducing the risk of the clinical consequences of aki (make) at 90 days in adult participants with ckd who undergo non-emergent cardiac surgery with cpb.


Eligibility criteria:
inclusion criteria: * participant weighs ≥ 30 kg * planned non-emergent sternotomy with cpb procedure for the following surgeries: * multi-vessel cabg * valve replacement or repair; ascending aorta surgery permitted if combined with aortic valve replacement/repair * combined cabg and valve surgery; inclusion of single-vessel cabg when combined with valve replacement/repair is permitted * known ckd for at least 90 days (ckd stage 3a, 3b, or 4) exclusion criteria: * emergency or salvage cardiac surgery is expected at screening or randomization, as assessed by the investigator. * single-vessel cabg without valve surgery is planned. * off-pump surgery is planned (eg, surgery without cpb). * recipient of a solid organ or bone marrow transplantation. * cardiogenic shock, hemodynamic instability, use of intra-aortic balloon pump, extracorporeal membrane oxygenation, or left ventricular assist device within 72 hours of randomization. * active systemic bacterial, viral, or fungal infection within 14 days prior to randomization. * history of unexplained, recurrent infection. * any use of krt or presence of aki within 30 days of randomization * use of any complement inhibitors, or plasmapheresis or plasma exchange within the year prior to screening, or planned use during the course of the study. * participant is not willing to be vaccinated against n meningitidis or is unwilling to receive prophylactic treatment with appropriate antibiotics , if needed * history of or unresolved n meningitidis infection.

Keywords: chronic kidney disease ckd cardiac disease cardiopulmonary bypass
using red djulis products can improve skin conditions

Conditions: Skin Condition

Summary: hypothesis: using red djulis products can improve skin conditions


Eligibility criteria:
inclusion criteria: 1. dry skin 2. rough skin 3. large pores 4. dark yellow complexion 5. sagging skin exclusion criteria: 1. skin disorders 2. liver diseases 3. kidney diseases 4. allergy to cosmetics, drugs, or foods 5. pregnant and lactating women 6. people who had any cosmetic procedures before 4 weeks of the study 7. area of facial spot over 3 cm2 8. vegan 9. people who took collagen supplements in the past 3 months.
dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: both warfarin and dabigatran have been used for stroke prophylaxis at the time of catheter ablation of atrial fibrillation. although the risks of thromboembolism and bleeding with warfarin are well established, the relative risk and benefit of dabigatran in this setting are unknown. the purposes of the study are to assess the efficacy of warfarin versus dabigatran in the prevention of stroke and other systemic embolic complications before and after catheter ablation for af, and to compare the prevalence of serious bleeding complications with the two oac agents.

* data from patients collected from 4 us and 1 canadian medical center * retrospective record review of all patients that had undergone catheter ablation of atrial fibrillation during the time period beginning with the initiation of dabigatran therapy for stroke prophylaxis at each center and ending in november 2011. * dabigatran study group comprised of all patients that received dabigatran for stroke prophylaxis during the study time period. * warfarin comparison group to be selected from all patients that received warfarin for stroke prophylaxis during the identical study time period. * warfarin patients will be numbered sequentially * a subgroup of warfarin patients identical in number to the dabigatran patients at each center will be selected using random number generator. patient data sets will be de-identified and compiled * master data set to be stored in excel file * statistics to be performed with sas (cary, nc) * continuous data to be expressed as means ± s.d., compared with unpaired t-tests * categorical data will be compared with fisher's exact test or chi-square * complications including any thromboembolic events or any bleeding events will be recorded and the prevalence compared.

Eligibility criteria:
inclusion criteria: * all patients undergoing catheter ablation for atrial fibrillation exclusion criteria: * none (retrospective trial)

Keywords: atrial fibrillation catheter ablation dabigatran warfarin oral anticoagulation
circulating tumor cells as tools for therapy response in nab-paclitaxel treated metastatic pancreatic cancer patients

Conditions: Metastatic Pancreatic Cancer

Summary: the majority patients diagnosed with pancreatic cancer have metastatic disease at the time of diagnosis. the prognosis is extremely poor with a 5-year survival rate of less than 5%. treatment with chemotherapy can improve efficacy, but still the median progression-free survival in patients receiving nab-paclitaxel and gemcitabine is only 5,5 months and median overall survival is less than one year. there is a urgent need for tools for predicting the efficacy of the treatment. the current trial aims at investigating the biomarker potential of circulating tumor cells (ctcs) in metastatic pancreatic cancer patients treated by gemcitabine and nab-paclitaxel.


Eligibility criteria:
inclusion criteria: * male or female \> 18 years up to 80 years * histologically or cytologically proven adenocarcinoma of the pancreas before start of treatment. also patients for whom there is a strong suspicion of unresectable pancreatic cancer will before the diagnosis is confirmed be asked for consent to take 2 additional biopsies at the time of diagnostic biopsy retrieval, in case the histological analysis confirms that they can be included. * locally advanced (primarily unresectable) and/or metastatic disease. * presence of at least one measurable lesion according to the recist criteria, not restricted to previously irradiated area or limited to bone, pleural effusion or ascites. * ecog/who performance status ≤2 * absolute neutrophil count (anc) \>1.5 x 109 /l and platelet count \>100 x 109/l * total bilirubin \ 2xuln, depending on increase of the bilirubin level according to the recommendations of the summary of product characteristics. * serum creatinin \ 60 ml/min. * written informed consent exclusion criteria: * current infection, bowel obstruction or subobstruction, or other uncontrolled intercurrent illness. * prior medical treatment for advanced pancreatic cancer * confirmed brain metastasis. * concurrent or past history of another malignancy except curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix. * treatment with any other investigational drug more than 30 days prior to study entry. * allergy to anyone of the included drugs. * female patient breast feeding or pregnancy * not able/ or not willing to use adequate contraception (defined below). a pregnancy test will be included in the baseline visit for women of childbearing potential.

Keywords: circulating tumor cells nab-paclitaxel metastatic pancreatic cancer gemcitabine
high risk populations among copd patients in japan

Conditions: COPD

Summary: the patients with complications of copd and asthma have features mixed with two diseases, copd and asthma. therefore, the outcomes are worsened if the patients with copd have symptoms overlapped with asthma, however, no sufficient data exist in japan for estimating the prevalence of acos in patients with copd. the primary objective of this nis is to clarify the proportion of acos defined by gina and gold in patients with copd. the main secondary objectives are to explore the features of history of copd exacerbations, symptoms, eosinophilic inflammation and patient background in patients with acos, to clarify the history of copd exacerbations in patients with copd, to evaluate the degrees of eosinophilic inflammation of the respiratory tract in patients with copd and to evaluate the symptoms in patients with copd. this is a cross-sectional study targeting copd patients receiving outpatient treatment and follow-up by physicians in japan. fsi is scheduled as 2q 2015 and dbl would be locked by 3q 2015.

study site(s), number of subjects planned number of study sites planned for this research study (scheduled) 60 (undetermined) number of subjects planned for this research study (scheduled) 1,100 patients

Eligibility criteria:
inclusion criteria * patients with a diagnosis of copd (fev1/fvc\<0.7 confirmed based on the past medical records) * patients aged 40 years and over at the diagnosis of copd * outpatient * 10 or more pack-years of current or former smokers * patients who have traceable medical records of copd (including the results of spirometry) going back more than a year * patients who meet any of the following two criteria 1. patients who have medical records of the results of spirometry at more than two different time points excluding the time point of copd exacerbations\* for the past 3 years 2. patients who can provide the results of reversibility testing for respiratory tract * patients who give written informed consent regarding the participation in this study exclusion criteria * patients currently with copd exacerbations * patients who currently enroll in the other interventional study including clinical trials * patients who concurrently develop or have a history of lung cancer * patients who are disabled to understand the study procedure or answer the questionnaire (i.e. due to the history of alcohol or drug abuse)
can education for rural women lift the fog behind closed doors?

Conditions: Contraception; Sexually Transmitted Diseases

Summary: the aim of this study was to investigate the effect of family planning and sexually transmitted diseases education given to rural women on their level of knowledge and attitudes towards reproductive health and family planning. design: the prospective, randomized controlled study


Eligibility criteria:
inclusion criteria: * women who can speak turkish, * are older than 18 years of age, * do not have a diagnosis of hearing impairment, * live with their husband/partner, * have an active sexual life, * live in the districts within the borders of bartın province, * do not have a type of cancer that may affect sexual function, * have not received family planning and sexually transmitted diseases training before, * have written informed consent, * volunteer to participate in the study exclusion criteria: * women who received family planning and sexually transmitted diseases education from another counselor during the study period, * did not participate in the post-test, * did not volunteer to participate in the study

Keywords: rural education knowledge attitudes
ketorolac in acute pancreatitis

Conditions: Acute Pancreatitis

Summary: this study will compare pain management strategies for patients hospitalized with acute pancreatitis. standard of care pain management will be compared to standard of care plus intravenous ketorolac.

patients hospitalized for acute pancreatitis and admitted to an internal medicine team will be eligible for study. patients enrolled will be blindly randomized to receive open-label pain management of standard of care or standard of care plus intravenous ketorolac. patients will be enrolled between hour 24 and 48 of hospitalization.

Eligibility criteria:
inclusion criteria: * 18 years old * opioid order for pain secondary to acute pancreatitis * diagnosis of acute pancreatitis defined by the presence of two of the following three criteria: abdominal pain, lipase \> 3x upper limit of normal, and/or findings of ap on imaging * a patient with acute-on-chronic pancreatitis that does not exhibit elevated lipase levels is eligible for inclusion if the patient has the other two criteria * received at least 3 l of iv crystalloid fluid within first 24 hours of admission to ensure patients have received initial volume expansion * hemodynamically stable represented by a mean arterial blood pressure (map) of ≥65 mmhg * female patients not documented in chart as post-menopause must have a negative pregnancy test exclusion criteria: * history of chronic heart failure * history of acute coronary syndrome (st-elevation myocardial infarction (stemi) or non-st elevation myocardial infarction (nstemi)) within last 6 months * history of ischemic or hemorrhagic stroke within last 6 months * history of upper gastrointestinal bleed (gi) within last 6 months * history of inflammatory bowel disease * history of cirrhosis * any overt, active bleeding requiring blood transfusion * considered to be high bleed risk (platelet \< 50,000/mcl) * pregnant or breastfeeding * prisoners * cognitively impaired patients: not alert and oriented to person, place, and time (patient must be able to consent) * allergy to nsaids, ketorolac, or aspirin * admission to an intensive care unit * evidence of infected pancreatitis (i.e. abscess) on imaging studies * acute kidney injury or chronic kidney disease with crcl\<30
left ventricular and endothelial function in preeclampsia

Conditions: Preeclampsia

Summary: the purpose of this study is (1) to examine whether the left ventricular function is impaired in women with preeclampsia relative to healthy pregnant controls, (2) to examine whether the endothelial function is impaired in women with preeclampsia relative to healthy pregnant controls, and (3) to examine whether there is a post partum impairment in left ventricular and endothelial function.


Eligibility criteria:
inclusion criteria: * \>18 years of age * case: clinical diagnosis of preeclampsia, * control: systolic bp \<140 mmhg and diastolic bp \<90 mmhg exclusion criteria: * known hypertension or other cardiovascular disease * diabetes/gestational diabetes * multiple gestation
susceptibility of cardiorespiratory responses to ozone during cycling exercise

Conditions: Ozone Exposure During Rest and Exercise

Summary: ground level ozone (o3) is a common airborne pollutant that is well recognized to cause negative respiratory symptoms and impair pulmonary function. the proposed study aims to have participants perform submaximal and maximal cycling exercise protocols exposed to both o3 and room air in a crossover design to evaluate how ventilatory patterns, pulmonary function, development of symptoms, and cycling performance are impacted by o3 exposure. additionally, the investigators look to compare responses between o3 at rest and during exercise to predict which subjects may be most susceptible to adverse response, as considerable interindividual variability exists.


Eligibility criteria:
inclusion criteria: * healthy males between the age of 18 and 50 * currently training and/or competing in endurance sport * vo2max \>60 ml/kg/min * able to communicate sufficiently using the english language exclusion criteria: * history of smoking * upper respiratory tract infection within the last 4 weeks * presence of any chronic respiratory disease

Keywords: ozone air pollution exercise cycling susceptibility ventilation
feasibility and acceptability trial of a culturally adapted manual versus standard cbt manual: a randomized control trial

Conditions: Anxiety; Depression

Summary: this randomized controlled trial (rct) will compare the efficacy and feasibility and acceptability of a culturally adapted cbt manual with a standard cbt manual, focusing on addressing cultural factors in therapy delivery.

randomized controlled trial (rct): participants will be randomly assigned to either the culturally adapted cbt manual group or the standard cbt manual group. a culturally adapted manual will integrate cultural values, norms, and idioms of suffering into cbt techniques, ensuring relevance and acceptance within the target cultural group. the standard cbt manual will follow conventional cbt techniques without specific cultural adaptations.

Eligibility criteria:
inclusion criteria: 1. individuals aged 18 to 65 years 2. 5 years of education 3. symptoms of depression and anxiety exclusion criteria: 1. substance use disorder according to dsm-5 criteria as determined by primary care clinician 2. significant cognitive impairment (for example, profound learning disability or dementia) as determined by primary care clinician 3. active psychosis as determined by their primary care clinician
cbt-i to improve functional outcomes in veterans with psychosis

Conditions: Insomnia; Psychosis

Summary: the goal of this project is to examine the efficacy of cognitive behavioral therapy for insomnia (cbt-i) for improving sleep and related functional outcomes in veterans with psychosis and insomnia.

the goal of this project is to examine the efficacy of cognitive behavioral therapy for insomnia (cbt-i) for improving sleep and related functional outcomes in veterans with psychosis and insomnia. aim 1: evaluate the efficacy of cbt-i for reducing insomnia severity in veterans with psychosis and insomnia. hypothesis 1: cbt-i participants, as compared to those in an active control condition, will show significantly greater reductions on the insomnia severity index at post-treatment and at a 6-month follow-up. aim 2: evaluate the efficacy of cbt-i for improving the functioning of veterans with psychosis and insomnia. hypothesis 2: cbt-i participants, as compared to those in an active control condition, will show significantly greater increases in mental and physical health functioning on the veterans rand 36-item health survey at post-treatment and at a 6-month follow-up. aim 3: evaluate the process that underlies the relationship between insomnia severity and functioning in veterans with psychosis and insomnia. hypothesis 3: the effect of cbt-i on mental and physical health functioning at post-treatment will be mediated by reductions in insomnia severity at week 5 of treatment. hypothesis 4: the effect of cbt-i on mental and physical health functioning at the 6-month follow-up will be mediated by reductions in insomnia severity at immediate post-treatment. exploratory aim: explore whether psychiatric symptoms 1) moderate the impact of cbt-i on insomnia and functioning and/or 2) change as a result of participation in cbt-i.

Eligibility criteria:
inclusion criteria: * meet criteria for smi: schizophrenic disorder, affective psychosis, major depression with psychotic features, delusional disorder, brief psychotic disorder, unspecified psychotic disorder, schizotypal personality disorder * be between the ages of 18 and 80 * be actively participating in outpatient mental health services at designated site exclusion criteria: * currently in cbt-i treatment * planning to move out of the area during the study period

Keywords: mental disorders insomnia disorder psychosis